Shots:
- The P-IIb Study 201 trial evaluates the efficacy of lecanemab vs PBO in 856 patients with MCI due to AD and mild AD
- The results showed robust clearance of brain amyloid and demonstrated clinical decline across multiple clinical and biomarker EPs. Additionally, the therapy showed consistent treatment effect across multiple statistical methods @18mos. for ADCOMS, CDR-SB, and ADAS-Cog14.
- Lecanemab is currently being evaluated in the P-III AHEAD 3-45 study in patients with preclinical AD, based on the P-II Study 201 study. A pre-specified analysis of Study 201 study demonstrated reduction of brain Aβ accumulation & slowing of disease progression in early AD
Click here to read the full press release/ article | Ref: Biogen | Image: Pharmaletter
The post Eisai Presents Results of Lecanemab in P-IIb Study 201 Study for the Treatment of Alzheimer’s Disease at CTAD 2021 first appeared on PharmaShots.
